New combo therapy aims to tame tough esophageal cancer
NCT ID NCT07530094
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the immunotherapy drug camrelizumab to a short course of chemotherapy and radiation can better control advanced esophageal cancer that cannot be removed by surgery. About 98 participants will receive one of two treatment schedules. The goal is to see if this approach improves how long the cancer stays under control and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Camrelizumab (an immunotherapy drug) combined with chemotherapy (nab-paclitaxel + carboplatin) and short-course radiation therapy
- What this could lead to
- If successful, this could offer a more effective treatment option for people with advanced esophageal cancer that cannot be surgically removed, potentially improving tumor control and survival.
- What could go wrong
- This is a Phase 2 trial with only 98 participants, so results are preliminary. The combination therapy may cause significant side effects, and the benefit over standard treatment is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jiangsu Cancer Hospital /Jiangsu Institute of Cancer Research
RECRUITINGNanjing, Jiangsu, 210000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.